Introduction
Pulmonary alveolar proteinosis (PAP) is an orphan lung disease, characterized by intra-alveolar accumulation of lipoproteinaceous material of unclear origin, which leads to gas exchange impairment and respiratory symptoms of variable severity. There are three different types of PAP: congenital PAP (2% of total cases), secondary PAP (less than 10% of total cases), and acquired or adult-type PAP (90% of cases). Currently, no curative treatment exists and sequential whole lung lavage remains the standard of care. More recently, granulocyte-macrophage colony stimulating factor (GM-CSF) has been proven to be involved in the pathogenesis of this condition, with possible therapeutic implications. The survival rate for adult PAP patients seems to have increased progressively in the last decades.
Historical overview
PAP was initially described in 1958 by three eminent pathologists, Rosen, Castleman and Liebow. 1 To date, less than 500 cases have been reported in the literature. 2 The first advance in the treatment of PAP came when Rivera J Ramirez applied 'repeated segmental flooding' as a means of physically removing the accumulated alveolar material. [3] [4] [5] Such 'segmental flooding' provided proof that physical removal of adequate amounts of the material provided improvement both in symptoms and pulmonary function tests. 6, 7 The further refined whole lung lavage (WLL) has become the 'gold standard' of PAP treatment.
The journey of discovery for PAP pathogenesis was marked by several distinct phases:
• A landmark laboratory observation was that mice with homozygous GM-CSF defective gene develop a PAP-like disease, while their hematopoietic function is normal. 8, 9 (BAL) of patients with idiopathic PAP but not in healthy controls. 10, 11 PAP may be the first human disease in which an autoantibody against a growth factor is linked to disease pathogenesis.
Over the last decade, advances in the understanding of PAP have led to the investigation of innovative therapeutic approaches.
Epidemiology
PAP has been reported to occur in a worldwide distribution and comprises three distinct subgroups: the acquired form, the congenital or neonatal form. Primary (idiopathic, acquired) PAP accounts for more than 90% of the cases. 2, [12] [13] [14] Its incidence has been estimated to be 0.37/100 000 persons and a prevalence of 3.7 per million of population. 15 At the time of diagnosis, the median age is around 40 years; most patients are men, and about three-quarters of them have a history of smoking. African-American patients comprise up to 17% of the reported cases from North America. 2 
Pathophysiology

Idiopathic PAP
Findings in humans and mice reveal that a congenital or an acquired defect in alveolar macrophage processing of surfactant proteins plays a critical role in the pathogenesis of PAP. Further, after therapeutic lavage in patients with PAP alveolar macrophages have a greater migratory capacity. 16 After their surfactant phagocytosis is exhausted, macrophages die and accumulate in the amorphous material. 17 Although surfactant clearance is impaired in PAP, synthesis of surfactant phospholipids and proteins is unperturbed. 18 The alveolar surface of normal lungs is lined by a thin layer of surfactant, which reduces the surface tension and prevents alveolar collapse. 19 It is composed of: (90-95%) lipids, ie, phosphatidylcholine, phosphatidylcholesterol, and (5-10%) proteins (surfactant proteins SP-A, SP-B, SP-C, SP-D). Some believe that Pulmonary Alveolar Phospholipoproteinosis would be a more appropriate term, since phospholipoproteins (especially dipalmitoyl phosphatidylcholine) represent the most abundant component of the alveolar material, while proteins represent only 2% of its content. Human lungs contain approximately 2-3 g of cholesterol, of which 40-60 mg is believed to be associated with the surfactant. Cholesterol is the most abundant neutral lipid in surfactant, constituting up to 90% of the neutral lipid material. 20, 21 At least 80% of the cholesterol in the lung and 100% from the surfactant derives from circulating lipoproteins, particularly very low density lipoproteins (VLDL). 22 While type II pneumocytes represent the major station for uptake, packaging, secretion, re-uptake and recycling of surfactant proteins, 23 it has been suggested that the elimination of cholesterol into cholestenoic acid may be an important step in the metabolism of the surfactant cholesterol by the alveolar macrophages. 20 Recent studies using high-resolution mass spectrometric alveolar proteomics 24 to determine the intra-alveolar matrix components have reached new knowledge frontiers, identifying structural modifications (hydroxyproline) and degradation products of surfactant proteins SP-A and SP-D, and hence contributed further to the understanding of the mechanistic basis of lung disease pathogenesis.
A landmark discovery came in 1994 when, unexpectedly, it was found that knock out GM-CSF mice used in different hematopoietic models developed a lung disease which was histologically similar to the human PAP, 8, 9 and felt to be the result of impaired surfactant clearance. 9,25 GM-CSF, 26 a 23 kDa growth factor, is encoded in humans and mice by a similar gene. 27 The discovery of GM-CSF had been published in 1977, 26 while in 1984 it became the first human cytokine to be cloned. 28 It has a potent capacity to augment the proliferation and differentiation of neutrophilic and monocyte-macrophage hematopietic lineages; in normal human individuals its administration leads to a dose-dependent response of peripheral neutrophilia, monocytosis and eosinophilia. 29 All of these actions occur downstream of specific highaffinity GM-CSF receptors, comprising two parts: ␣ chain (binding unit) and common ␤ c chain (signal transduction unit, named 'common' because it is also part of the receptors for IL-3 and IL-5). The cell surface receptors are present on hematopoetic cells and alveolar macrophages. [30] [31] [32] In 1994, two independent centers reported the creation of knock-out mice for the GM-CSF gene; the animals had preserved fertility, normal hematopoiesis and viability. 9, 33, 34 The deficient homozygous mice, as opposed to heterozygous or normal mice, developed as early as four weeks postnatally a PAP-like disease in their lungs. 8, 9 These findings suggested a critical role of GM-CSF in normal surfactant homeostasis, which was later confirmed by another discovery: the ␤ c chain gene homozygous deletion confers a similar susceptibility to PAP (as explained in the congenital PAP section). 35, 36 Exogenous administration of aerosolized GM-CSF corrected the lung lesions in the GM-CSF knock-out mice. 37 Furthermore, stem cell transplantation and hematopoietic reconstitution of GM-CSF deficient mice have been shown to reverse the pulmonary lesions of PAP. 38, 39 Interleukin-4 (IL-4) may also play a role in surfactant homeostasis, since its action on pulmonary Clara cells leads to increased surfactant synthesis, and subsequently, a PAP-like disease. 40 Human studies have confirmed the pivotal role of GM-CSF in PAP pathogenesis. Adult patients with PAP had impaired hematologic response to GM-CSF supplementation. 41, 42 High doses of GM-CSF could still lead to a response thereby suggesting that the response to GM-CSF was impaired and not totally absent. 42 Lack of GM-CSF production does not seem to play any role in human PAP. 43, 44 However, several authors have showed that human PAP may be related to a decreased GM-CSF pathway activity. 10, 11 Kitamura et al. 10 reported a neutralizing IgG antibody against GM-CSF in BAL from 11 patients and sera of five patients with idiopathic PAP, but not in secondary PAP, healthy controls or patients with other lung disease. In a parallel study from the Cleveland Clinic we found specific antibodies against GM-CSF in the lungs and sera of 40 adults with idiopathic PAP but not in control subjects. 45 These reports support the theory that a relative GM-CSF deficiency seen in acquired PAP may be due to the neutralizing antibody against GM-CSF. Moreover, the systemic antibody production provides an explanation for the recurrence of PAP following double lung transplantation. 46 
Congenital PAP
Congenital PAP was first described in 1981 in a consanguineous family of four affected siblings. 47 Most cases of congenital PAP are transmitted in an autosomal recessive fashion 47, 48 and caused by homozygosity for a frame shift mutation (121ins2) in the surfactant protein B gene (SP-B) 49 that leads to an unstable SP-B mRNA, culminating in SP-B deficiency, which leads to secondary disturbances of surfactant protein C (SP-C) processing. 50 There are infants with neonatal onset PAP who do not have any disturbances of SP-B expression; in these cases, the primary abnormality is in the GM-CSF receptor ␤ c chain. The initial studies in knock-out mice have shown that a mutation of ␤ c chain of the GM-CSF/IL-3/IL-5 receptor leads to PAP. 38 A similar mutation has been described by others, 51 who found it in three out of seven pediatric patients with congenital PAP, and in one patient with a PAP-like disease. This report provided evidence that a defect in the expression of a hematopoietic cytokine receptor is associated with human PAP. 51
Secondary PAP
PAP has been associated with various conditions, such as silicosis, immunodeficiency disorders, hematological conditions or malignancies. An acute form of silicosis has been called 'acute silico-proteinosis' to emphasize the histological similarity to PAP. 52, 53 This was associated with heavy, short-term exposure to high concentrations of free silica particles. Other environmental or industrial materials such as aluminium dust, 54 fibrous insulation fibers, 55 cement dust, 56 titanium dioxide 57 and nitrogen dioxide, 58 have been associated with PAP development.
PAP also occurs in association with several hematopoietic disorders, in which a functional impairment or a quantitative cytopenia of the bone marrowderived alveolar macrophages exists. Hematologic malignancies, predominantly myelogenous leukemias are well established causes. [59] [60] [61] [62] This observation is supported by the resolution of pulmonary process after the restoration of normal hematopoietic function. 63 Immunodeficiency disorders such as thymic alymphoplasia, 64 and IgA deficiency, 65 or acquired states such as solid organ transplantation, 66 treatment with imatinib mesylate 67 and acquired immune deficiency syndrome 68, 69 have been associated with PAP. Infections with mycobacteria, 70-73 nocardia, 74 cytomegalovirus, 69 pneumocystis carinii 69, 75 and anerobes 76 have also been associated with PAP.
Clinical presentation
Clinical presentation is variable and nonspecific. The nonspecific nature of presentation and insidious onset may lead to months and sometimes years until diagnosis. Similar to sarcoidosis, in PAP the symptoms are frequently modest compared to the radiological findings (clinical-radiological discrepancy). Based on the published case reports and case series (almost 500 patients altogether), the clinical features of patients with PAP are relatively well characterized 2,12,77,78 (Table 1) . Although PAP spans all ages, the typical adult PAP patient has a median age of 39 years, and has a history of progressive dyspnoea, and cough. Fifty percent of the patients have the above symptoms for less than seven months; another 25% of patients report having symptoms of two years or longer. Up to a third of the PAP cases may be minimally symptomatic. 77 Some present acutely with pneumonia-like symptoms, and the remaining present with subacute or chronic symptoms and radiologically with nonresolving infiltrates. Less common symptoms include fatigue, weight loss and low-grade fever. Cough is mostly nonproductive and may be absent in at least one-quarter of patients, unless there is complicating pulmonary infection. Less than 20% of patients report hemoptysis or chest pain. Secondary pulmonary infections may occur in up to 13% of cases, with Nocardia sp. being notorious. 2 Overall, up to three-quarters of patients are smokers at the moment of presentation. It is unclear if the male gender preponderance is related to smoking habits (more prevalent in men). There have been rare reports of pneumothorax 79 and cor pulmonale 80 in PAP.
As physical examination is commonly unrevealing, the respiratory system's examination may show crackles (in half of the patients), clubbing and/or cyanosis (in up to one-quarter in earlier case series). 12, 77, 78, 81 
Imaging studies
Chest radiography is the most useful screening test, although very nonspecific. 82, 83 Typically, a pattern of bilateral, symmetric alveolar-type of infiltrates is seen. Perihilar opacities extending into the periphery, slightly more pronounced in the upper lobes, yielding a 'butterfly' distribution and sparing the costophrenic angles is the typical description. The typical picture seems less common in most disease descriptions. 2, 14, 84 Sometimes a mixed, alveolar-interstitial, or nodular pattern can be described.
The chest CT scan imaging has a higher diagnostic yield and specificity, 85 confirming the alveolar consolidation with or without air bronchograms (pneumonic from), or the ground-glass opacifications with interlobular septal thickening ('crazy-paving' pattern; Figures 1 and 2) . These radiologic appearances may suggest PAP but are still nonspecific, being found in other conditions, too. 86, 87 Variable degrees of interstitial fibrosis may be encountered, although honeycombing is rarely seen. [88] [89] [90] The extent and severity of these changes, especially if carefully quantified, show good correlation with the degree of functional impairment. 82
Functional evaluation
Spirometry generally shows a restrictive ventilatory defect of variable severity. Carbon monoxide diffusing capacity (DLCO) is decreased, and its impairment does not correlate with the fall in vital capacity. 12, 82, 91 Arterial blood gas analysis shows mild to moderate hypoxemia, with an elevated alveolar-arterial gradient 12, 14, 77 and elevation in shunt fraction. 92
Laboratory investigation
Broncho-alveolar lavage (BAL) may help in establishing the diagnosis in clinically suspected cases. BAL fluid may have a 'milky' appearance, with large amounts of granular, acellular eosinophilic lipoproteinaceous material which is Periodic acid schiff (PAS) Dyspnea  63  79  52  79  Cough  33  59  24  79  Chest pain  22  32  3  13  Hemoptysis  -24  -17  Clubbing  11  29  6  25  Crackles  15  18  31  50  Cyanosis  19  24  4  21  Fever  22 positive and diastase resistant. 93, 94 Papanicolaou stained smears of the BAL fluid specimen reveals globules (stained green, orange or orange in center coated with a green rim) which can be of significant value in making a diagnosis of PAP, 95 especially when the number of globules is more than 18. Concentrically laminated structures called lamellar bodies which are seen on electron microscopic exam of BAL fluid can confirm the diagnosis; they have a phospholipidic structure. 96, 97 Serum and BAL lactate dehydrogenase (LDH) levels have been shown to be elevated but this is not a pathognomonic feature. 98 KL-6, a mucin like protein secreted by type II pneumocytes is elevated in serum and BAL fluids of PAP patients but it is also nonspecific; 99 the receiver-operator characteristic (ROC) curve for KL-6 seems to be the most favorable for the diagnosis among other tests. 100 Surfactant protein A (SP-A) and surfactant protein D (SP-D) are elevated in the sera of PAP patients, but also in idiopathic pulmonary fibrosis and pulmonary edema. [101] [102] [103] [104] Recently, monocyte chemotactic proteins MCP-1, MCP-2, MCP-3 have been shown to be elevated in BAL of PAP patients, while the expression of chemokine chemotaxis receptor CCR-2 on alveolar macrophages and peripheral lymphocytes is decreased, possibly by an autocrine feedback mechanism exerted by MCP-1. 105, 106 Obtaining tissue for histopathology by open lung biopsy has remained the 'gold standard'. Transbronchial biopsies may be occasionally nondiagnostic, due to the 'mosaic' pattern of the disease, although more recent reports and series show a higher yield than historical low numbers. Surgical lung biopsy is sometimes necessary to make the diagnosis. 12, 77, 85 The characteristic biopsy features of PAP on light microscopy (Figures 3 and 4) is the intra-alveolar and terminal bronchioles' filling with PAS positive material. The alveolar and interstitial architecture are usually well preserved, except for late pulmonary fibrosis. Electron microscopy reveals the multilamellated structures with in the alveolar material as well as the cytoplasmic inclusions of macrophages. 14, 107 Furthermore, anti-GM-CSF antibodies are increasingly used as a diagnostic tool in PAP. Even though the bronchoscopic investigation remains an important step in excluding opportunistic infections and alternative diagnoses, the quantitative assessment of anti-GM-CSF antibodies in reference laboratories constitute an important diagnostic and therapy-guiding measurement.
Differential diagnosis
A diagnosis of PAP should be entertained in any patient, previously healthy, with progressive dyspnoea on exertion and alveolar filling pattern radiographically. A combination of consolidations and groundglass opacities in a 'batwing' distribution, traditionally in the mid-lung zones, with sparing of the costophrenic and vertebrodiaphragmatic spaces and the reticular infiltrates suggesting 'crazy pattern' has been advocated to be highly suggestive. This radiological appearance, although nonspecific, warrants differentiation from other sources of intra-alveolar fluid (edema, exudates, blood, pus, etc.).
It should be remembered that the idiopathic PAP is a diagnosis of exclusion. Environmental exposures to aluminum powder, titanium materials, silica dust, cement, fiberglass, silicon dioxide, insulation materials, etc., hematological and malignant conditions (Hodgkin and non-Hodgkin lymphoma, acute myelogenous and lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, multiple myeloma, myelodisplastic syndrome, melanoma, amyloidosis, myeloproliferative disorders, monoclonal gammopathy, etc.), immunodeficiency syndromes (severe combined and selective IgA deficiency), dermatomyositis/polymyositis and allogeneic lung transplantation are conditions rarely associated with PAP. Alveolar proteinosis is also associated with different infections, caused by Nocardia, Aspergillus, Cryptococcus, Mycobacteria, Pneumocystis carinii or Histoplasma capsulatum spp. It is a conjecture that these organisms could be the etiological agents of secondary PAP, while the explanation that these infections are in fact opportunistic in nature and superimposed on pre-existent PAP seems more acceptable.
Hereditary deficiency of SP-B protein leads to intracellular accumulation of proSP-C in affected infants, while another congenital disorder, lysinuric protein intolerance may present with pathological patterns identical to PAP or alveolar hemorrhage.
Treatment
The treatment of PAP depends on the form: (1) congenital PAP -supportive 13 or lung transplantation; 108 (2) secondary PAP-treatment of underlying condition or removal of offending agent; 67, 109 (3) idiopathic PAP -whole-lung lavage, GM-CSF or plasmapheresis. 2, 44, 100, 110 
Whole-lung lavage
Whole-lung lavage (WLL) represents a method of physically removing the excess alveolar lipoproteinaceous material (for the radiographic results, see Figure  2 ). Overall, approximately 63% of total PAP cases undergo WLL within five years from diagnosis; furthermore, less than 20% of those patients followed beyond three years remaining free of recurrent PAP manifestations. 2 Although physical removal of the lipoproteinaceous material through repeated dilution with saline solution is believed to be the mechanism for the beneficial effects of WLL, additional mechanisms including the bulk removal of anti-GM-CSF antibody as well as other possible immunologic effects on the effector cells, such as the alveolar macrophage or the type II epithelial cell are possible. 111 In 1964, Ramirez performed a trial of WLL using up to 3 L of saline (with heparin or acetylcysteine) under local anesthesia. 5 Subsequently, WLL has seen refinement in the form of routine use of general anesthesia, 112, 113 increased lavage volumes, saline used alone, 114, 115 addition of chest percussion, 114, 116 modified techniques 117, 118 and the successful completion of bilateral sequential WLL in the same session. 78 In our institution, we have compared bilateral sequential with unilateral WLL and have found that bilateral approach was as safe as unilateral WLL. Furthermore, the length of stay was significantly lower with bilateral WLL and there was a nonsignificant trend towards improved oxygenation with bilateral WLL. 119 Forced vital capacity (FVC), total lung capacity (TLC), partial pressure of oxygen (PaO 2 ), both at rest and with exercise and diffusing capacity (DLCO) all increased markedly, while alveolar-arterial gradient and shunt fraction decreased significantly after WLL. 120 The patients described in the original reports of PAP as 'responders' had larger quantitative improvement in functional parameters compared to 'nonresponders', although not statistically significant. The median changes for 'responding' patients was PaO 2 +20 mmHg, A-aDO 2 -33 mmHg, FEV 1 +210 mL, vital capacity (VC) +520 mL and DLCO +4.5 mL/min . mmHg. 2 There have been reports about gradual radiographic clearing, 121 improved alveolar macrophage migration 16 and improved ventilation/perfusion matching on scintigraphy 122 after WLL.
The impact of WLL on the natural history of idiopathic PAP is difficult to ascertain, given the absence of randomized prospective trials or large, long-standing registries. The median symptom-free period after one session of WLL is 15 months, and repeat treatments are generally required. 2 More than 60% of patients have a good symptomatic response within two lung washes/lung, ie, have a complete return to normal exertional capacity. 78 With regard to survival, in an analysis of the literature, Seymour et al. 2 found that those patients who underwent WLL at any time during the course of their disease had a five-year survival of 94 Ϯ 2% versus 85 Ϯ 5% for those never receiving such treatment (P = 0.04).
There are no standard indications for WLL, although the following criteria have been proposed: daily-life activity -impairing dyspnea, 123 PaO 2 Ͻ 60 mmHg 77 and shunt fraction Ͼ10-12%. 120 Possible complications related to WLL are: hypoxemia, pneumonia, sepsis, adult respiratory distress syndrome and pneumothorax. 14, [124] [125] [126] [127] Although fairly well tolerated, WLL usually provides temporary symptomatic benefit, but requires prolonged general anesthesia, is complex to perform, is associated with potential morbidity and fails to correct the primary defect in PAP. Hence, the search for alternative modalities of therapy.
GM-CSF therapy
The first case report of a patient treated successfully with GM-CSF came from Seymour et al., in 1996. 128 After this, two published prospective studies of subcutaneous GM-CSF therapy of patients with PAP have been published. 41, 129 In one study, a favorable response was noted in 6 out of 14 patients (43% response rate, 95% confidence interval 18%-71%) treated with 5 g/kg/day of GM-CSF for 6-12 weeks, 129 despite having pre-existing serum GM-CSF neutralizing antibodies; the response lasted a median of 39 weeks, range 6 to 67 weeks. 100, 129 In a study at our institution, seven adult patients with biopsy-proven idiopathic PAP were treated with selfadministered, once daily, subcutaneous GM-CSF for a minimum of 12 weeks. Five of them (71%) experienced symptomatic, physiologic and radiographic improvement. Improvement in oxygenation was not apparent until 8 to 12 weeks after start of therapy and the peripheral white blood cell count did not increase in any of the patients. 130 In another analysis, using GM-CSF at 5-18 g/kg/day for 10-48 weeks (median, 26 weeks), in 6 out of 13 patients (46%) was noticed an improvement of more than 10 mmHg of the arterialalveolar gradient, associated with symptomatic and radiologic improvement 131 In 11 patients who completed initially the Cleveland Clinic GM-CSF open label clinical trial, it was demonstrated that the level of anti-GM-CSF titer is higher in patients with active disease and is lower in patients in remission. 110 The anti-GM-CSF titer at baseline was lower and decreased further in responders to GM-CSF therapy. GM-CSF therapy did not induce or further increase the anti-GM-CSF titer and all PAP patients had a suppressed leukocyte response to GM-CSF and it appeared that an increase in systemic eosinophils may predict response. 131 Longer time from diagnosis, higher vital capacity, normal serum levels of lactate dehydrogenase and a higher plasma level of SP-B (each P Ͻ 0.04) were associated with a response to GM-CSF (5 g/kg/day). 129 In analyzing the subsequent data at the Cleveland Clinic Foundation in 2004, 21 out of 25 patients enrolled completed a trial of rhGM-CSF escalated to effect. Nine patients (43%) did not achieve clinical, radiological or functional improvement (nonresponders), while 12 patients (57%) had a good clinical response ('responders'). In the 'responders' group the radiologic scores improved in all patients, total lung capacity increased on average by 0.9 L, DLCO improved on average by 5 mL/min/mmHg, and the mean arterial-alveolar oxygen gradient decreased by 20.8 mmHg. 132 There have been an additional seven published case reports [133] [134] [135] [136] [137] [138] [139] of subcutaneous GM-CSF at dosages of 3-8 g/kg/day, with six of them responding to the therapy. One case report of clinically successful treatment of PAP with GM-CSF described a profound reduction in GM-CSF neutralizing autoantibodies (both serum and BAL) and improvement in alveolar macrophage morphology and function. 139 Taken together, all these articles demonstrate an overall response rate of 17/33 (52%, 95% confidence interval 34-69%) to GM-CSF. 100 GM-CSF therapy is generally well tolerated. Erythema and induration at injection site has been described in 36% of patients with a dose of 5 g/kg/day. 129 One reported patient developed neutropenia during treatment, which resolved after cessation of GM-CSF. 42 Fever, chills, nausea and vomiting within four hours of administration have been described in four patients. The symptoms occurred after varying periods of treatment (range one to 35 days) and they resembled the 'first dose effect'. 129 A syndrome of hypoxia and hypotension that follows the first but not subsequent doses of GM-CSF has been recognized. Thirteen of 42 patients receiving GM-CSF in phase I studies and four of six patients in a phase II study developed a reaction characterized by flushing, tachycardia, hypotension, musculoskeletal pain, dyspnoea, nausea and vomiting, rigors, involuntary leg spasms and syncope. The reaction did not occur after more than 10 minutes and subsequent consecutive GM-CSF doses. 140 Although there have been no reports of any late toxicity with GM-CSF therapy, longer surveillance is necessary to define long-term effects. GM-CSF therapy has been used as aerosol therapy in cancer patients with pulmonary metastasis 141 and the successful use of aerosolized GM-CSF has also been described. 142, 143 Although a positive effect of GM-CSF has been shown in idiopathic PAP, many important questions remain, including that of the optimal dose of GM-CSF, the optimal duration of treatment, the relation to the anti-GM-CSF titers and the optimal route of GM-CSF administration. One case report has described a benefit from plasmapheresis in PAP. 131
Supportive therapy
Respiratory infections are common in PAP, often with atypical organisms including Nocardia. Any suspicion of a respiratory infection should lead to an aggressive microbiological investigation, including bronchial washings and broncho-alveolar lavage.
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Therapeutic measures of supplemental oxygen, bronchodilators, antibiotics or respiratory support, when appropriate, are all part of the conventional modes of therapy, directed at associated infections, bronchospasm, respiratory failure and so on. Use of steroids is generally deleterious in this setting through interference of surfactant maturation and secretion. Pulmonary rehabilitation may also be helpful.
Lung transplantation
Double (or anecdotally, single) lung transplantation is a therapeutic measure employed in congenital forms of PAP, when WLL is deemed unsuccessful, when PAP is associated with other fibrosing lung conditions, such as silicosis or when recurrent pneumothorax is a recurrent complication of the disease or of the WLL. In lung allograft recipients, on the other hand, diffuse alveolar damage represented by reperfusion injury, rejection and/or infection may herald the development of intra-alveolar accumulation of granular, periodic acid-Schiff-positive material in the allograft lungs. It has been postulated that immunosuppressive therapy combined with defective alveolar clearance by local macrophages leads to the accumulation of surfactant, lipoprotein, and fibrinous debris that is morphologically identical to alveolar proteinosis. 46, 66, 108, 144 
Natural history
The natural history of PAP is still incompletely known. Case reports and relatively small case series pointed out that spontaneous disease remission or long quiescent periods can be seen in certain patients. On a long-term basis, this can be a significant confounder in judging the response to different therapeutic modalities. In a series of 24 patients with PAP, followed for 8.5 years, six deaths occurred (all not attributable to PAP complications); half of the survivors had persistent symptoms, such as cough, chest pain or wheezing. 12 In another series of 21 patients, 145 all treated with WLL, a recurrence rate less than 30% was noted, although residual symptomatic and functional impairment remained, even in the absence of new PAP exacerbations.
What seems to be generally accepted is that, once the disease is diagnosed, its outcome seems to be much better, when compared to old, historical data; survival rate close to 100% in the last 10 years have been noted. 2 Prior to widespread use of WLL, mortality rates close to 30% have been reported. 146, 147 Given the low mortality of the disease during the era of WLL, follow-up on a 'as needed' or yearly basis has been advocated, as opposed to more quantitative measurements, which would conceivably show a more prevalent pattern of disease persistence. Deaths in PAP are mainly related to infections (up to 20%), and respiratory failure (roughly 80%). Overall, diseasespecific survival rates exceed 80% at five years. 100
Summary
In conclusion, PAP is an orphan lung disease characterized by recurrent accumulation of lipoproteinaceous material in the lungs with minimal associated inflammation or interstitial fibrosis. Its pathogenesis has been partially deciphered, especially through the implication of GM-CSF and anti-GM-CSF antibodies in the idiopathic form. These advances have resulted in the use of GM-CSF as therapy for adult PAP. This may supplement and hopefully may eventually replace sequential whole lung lavage, which is the current standard of care.
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